Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
– Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation –
CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq:SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced that an abstract outlining the SYNB1353 program as a potential treatment for homocystinuria (HCU), including findings from fermentation process improvements to increase activity of methionine degradation, has been accepted and will be presented at the International Conference on Microbiome Engineering 2023, held in Berkeley, California on December 8th to 10th.
Related news for (SYBX)
- Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
- Sidoti Events, LLC’s Virtual January Micro-Cap Conference
- Synlogic Provides Corporate Update and Outlook for 2024
- Synlogic Announces Contract with the Air Force Research Lab